Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From scPharmaceuticals, Inc.
The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
- Drug Delivery